Abstract
The human breast and ovarian cancer susceptibility gene BRCA1 is a tumorsuppressor gene which is mutated and lost in hereditary breast and ovarian cancer, and has both alleles mutated in approximately 10-15% of cases of sporadic ovarian cancer. Studies of chromosome loss in ovarian cancer show that at least one allele of the BRCA1 gene is lost or mutated in up to 70% of sporadic ovarian cancers. Although no sporadic breast cancers contain BRCA1 mutations, our published study shows that expression of the mRNA is decreased suggesting that the BRCA1 gene is altered quantitatively in sporadic cancer and qualitatively in hereditary cancer. Decreased expression of the BRCA1 gene may also be important in cases of sporadic ovarian cancer that do not have BRCA1 mutations. The majority of mutant alleles are nonsense and should produce truncated proteins, which are predicted to vary in length from 5% to 99% of full-length protein. A relatively small number of missense mutations have also been identified, most commonly in the predicted ring finger domain in the N-terminus. Patients with mutations in BRCA1 differ clinically from nonfamilial breast cancer because the breast cancer is earlier in onset and more highly associated with ovarian cancer. We have recently obtained data indicating that families with BRCA1 mutations in the 3′ portion of the gene develop early-onset breast cancer, but do not develop ovarian cancer, suggesting that expression of a truncated BRCA1 protein may suppress ovarian tumors, but not breast tumors (1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Holt, J. T., Thompson, M. E., Szabo, C., Robinson-Benion, C., Arteaga, C. L., King, M-C., and Jensen, R. A. (1996) Growth retardation and tumor inhibition by BRCA1. Nature Genet. 12, 298–302.
Steeg, P. (1996) Granin expectations in breast cancer? Nature Genet. 12, 223–225.
Jensen, R. A., Thompson, M. E., Szabo, C., Jetton, T., van der Meer, R., Helou, B., et al. (1996) BRCA1 is secreted and exhibits properties of a granin. Nature Genet. 12, 303–308.
Holt, J. T., et al. (1998) Growth retardation and tumor inhibition by BRCA1 (correction). Nature Genet. 19, 102.
Arteaga, C. L. and Holt, J. T. (1996) Tissue-targeted antisense anti-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res. 56, 1098–1103.
Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., and Holt, J. T. (1995) Decreased expression of BRCA1 accelerates growth and is frequently present during sporadic breast cancer progression. Nature Genet. 9, 444–450.
Obermiller, P. S., Pilaro, A. M., Arteaga, C. L., and Holt, J. T. (1997) Inflammation alters distribution of antifos retroviral vector after murine intracavitary delivery, in Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors (Wickstrom, E., ed.), Marcel Dekker, New York.
Tait, D. L., Obermiler, P. S., Redlin-Frazier, S., Jensen, R. A., Welcsh, P., Dann, J., et al. (1997) Phase I trial of BRCA1 retroviral gene therapy for ovarian cancer. Clin. Cancer Res. 3, 1959–1968.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Obermiller, P.S., Holt, J.T. (2000). Ovarian Cancer Gene Therapy with BRCA1—An Overview. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Medicine™, vol 35. Humana Press. https://doi.org/10.1385/1-59259-086-1:593
Download citation
DOI: https://doi.org/10.1385/1-59259-086-1:593
Publisher Name: Humana Press
Print ISBN: 978-0-89603-714-4
Online ISBN: 978-1-59259-086-5
eBook Packages: Springer Protocols